WO2008059810A1 - Dispositif d'injection de médicament - Google Patents
Dispositif d'injection de médicament Download PDFInfo
- Publication number
- WO2008059810A1 WO2008059810A1 PCT/JP2007/071954 JP2007071954W WO2008059810A1 WO 2008059810 A1 WO2008059810 A1 WO 2008059810A1 JP 2007071954 W JP2007071954 W JP 2007071954W WO 2008059810 A1 WO2008059810 A1 WO 2008059810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ultrasonic wave
- amplitude
- drug
- unit
- modulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
Definitions
- the present invention relates to a drug injection device that injects a drug supplied to the surface of an injection target such as a human body into the body of the injection target using ultrasonic vibration.
- drug administration methods include oral methods, injection methods, and non-invasive methods.
- the injection method is the only method that directly administers blood vessels, and is widely used.
- a non-invasive method a method using percutaneous penetration using ultrasonic waves is considered (see Patent Document 1).
- Patent Document 1 Pamphlet of International Publication No. 2003/061753
- Patent Document 2 Japanese Patent Laid-Open No. 2004-249025
- the present invention has been made in view of the above-described problems, and realizes efficient injection according to a drug when the drug is injected onto the surface of an injection target such as a human body using ultrasonic waves.
- the object is to provide a drug injection device.
- a drug injection device includes a drug supply unit that supplies a drug to the surface of the injection target, and a surface of the injection target that is supplied with the drug. Based on the ultrasonic oscillator that oscillates the amplitude-modulated ultrasonic group in which the amplitude of each ultrasonic wave is modulated, and the drift velocity of the drug with respect to the injection target, A control unit for controlling the amplitude of each ultrasonic wave.
- FIG. 1 is a block diagram showing a schematic configuration of a drug injection device according to a first embodiment of the present invention.
- FIG. 2 is a schematic diagram showing an amplitude-modulated ultrasonic wave group oscillated from the ultrasonic oscillating unit to the skin of the injection target and its harmonic probability function.
- FIG. 3 is an equivalent circuit diagram of a dynamic model at the positive distortion amplitude of a sin wave.
- FIG. 4 shows a comparative example, and is a photograph showing a state of diffusion of a drug (a food coloring pigment dissolved in glycerin) when an ultrasonic wave having a fixed amplitude is oscillated from an ultrasonic wave oscillating unit of the drug injection device. is there.
- a drug a food coloring pigment dissolved in glycerin
- FIG. 5 is a diagram illustrating diffusion of a drug (a food coloring pigment dissolved in glycerin) when an amplitude-modulated ultrasound group is oscillated from the ultrasound oscillation unit of the drug injection device according to the first embodiment of the present invention. It is a photograph showing the appearance of.
- a drug a food coloring pigment dissolved in glycerin
- Fig. 6 is a diagram illustrating a case where each drug is injected into an object to be injected (specifically, when the amplitude-modulated ultrasonic wave group is oscillated from the ultrasonic oscillation unit of the drug injection device according to the first embodiment of the present invention
- Fig. 6 is a characteristic diagram showing the diffusion concentration diffused into a 20 cc pure water through a lmm-thick porcine bladder membrane.
- FIG. 7 is a block diagram showing a schematic configuration of a drug injection device according to a second embodiment of the present invention.
- FIG. 1 is a block diagram showing a schematic configuration of a drug injection device 100 according to the first embodiment of the present invention.
- the drug injection device 100 is configured to include a drug supply unit 110, an ultrasonic oscillation unit 120, a control unit 130, an information input unit 140, and a drift velocity value storage unit 150. ing.
- the drug supply unit 110 supplies a drug to the surface (skin 201) of an injection target (in this embodiment, for example, a human body) 200.
- the drug supply unit 110 includes a storage unit 111 for storing a drug (in this embodiment, a liquid drug) 11 la, a drug holding buffer 113 disposed on the surface of the injection target 200, and a storage unit 111.
- the drug injection tube 112 for guiding the drug 11 la to the drug holding buffer 11 3 and the injection of the drug 11 la provided in the drug injection tube 112 and supplied to the drug holding buffer 11 3 Constructed with a valve 114 for adjusting the amount!
- the noreb 114 is controlled by the CPU 133 of the control unit 130.
- the ultrasonic oscillating unit 120 includes, for example, a piezoelectric element (not shown) such as PZT, and the injected body 200 to which the drug 111 a is supplied via the drug holding buffer material 113.
- An amplitude-modulated ultrasonic wave group in which the amplitude of each ultrasonic wave is modulated is oscillated on the surface (skin 201). Due to the oscillation of the amplitude-modulated ultrasonic wave group by the ultrasonic wave oscillating unit 120, the drug 11 la held in the drug holding buffer 113 is injected into the body 202 of the injection target 200 through the skin 201.
- the information input unit 140 inputs, for example, various types of information including information related to the type of drug 11 la to be used and information related to the injection amount of the drug to the CPU 133 of the control unit 130.
- the drift velocity value storage unit 150 stores a plurality of drift velocity values.
- the drift velocity value storage unit 150 stores a drift velocity value for each type of drug 11 la.
- the control unit 130 controls the amplitude of each ultrasonic wave of the amplitude-modulated ultrasonic wave group oscillated from the ultrasonic wave oscillating unit 120 based on the drift velocity of the drug 11 la with respect to the injection target 200.
- the control unit 130 includes an oscillation ultrasonic detection unit 131, an ultrasonic amplitude extraction unit 132, a CPU 133, an ultrasonic amplitude adjustment unit 134, a phase detection unit 135, a resonance frequency adjustment unit 136, an AC voltage transmission Unit 137, voltage control amplifier 138, and power amplification unit 139.
- the oscillating ultrasonic wave detection unit 131 detects each ultrasonic wave of the amplitude-modulated ultrasonic wave group oscillated from the ultrasonic wave oscillating unit 120 as a voltage value.
- the ultrasonic amplitude extraction unit 132 extracts the amplitude as a voltage value for each ultrasonic wave detected by the oscillation ultrasonic wave detection unit 131.
- the CPU 133 controls the overall operation of drug injection device 100. For example, the CPU 133 extracts the corresponding drift velocity value from the drift velocity value storage unit 150 according to the type of the drug 11 la input from the information input unit 140, and based on the extracted drift velocity value! Then, a control signal for controlling the amplitude of the amplitude-modulated ultrasonic wave group oscillated from the ultrasonic oscillator 120 is transmitted to the ultrasonic amplitude adjuster 134. For example, the CPU 133 determines the amount of the drug 11 la to be supplied from the storage unit 111 to the drug holding buffer 113 based on the information related to the injection amount of the drug 11 la input from the information input unit 140. And the number of each ultrasonic wave oscillated as one amplitude-modulated ultrasonic wave group is determined from the ultrasonic oscillator 120, and a control signal based on the determination is transmitted to the ultrasonic amplitude adjuster 134.
- the CPU 133 shows a control signal for controlling the amplitude of the amplitude-modulated ultrasonic group and a control signal related to the number of ultrasonic waves oscillated as the amplitude-modulated ultrasonic group as shown in FIG. Output as sawtooth signal voltage.
- the slope (slope) of the monotonically increasing portion of the saw tooth corresponds to the value of the extracted drift velocity, and each ultrasonic wave that oscillates as one amplitude-modulated ultrasonic wave group depending on the on-time of the saw tooth. Control the number of
- the ultrasonic amplitude adjusting unit 134 receives the voltage value related to the amplitude of each ultrasonic wave extracted by the ultrasonic amplitude extracting unit 132 and the sawtooth signal voltage from the CPU 133, and oscillates from the ultrasonic wave oscillating unit 120.
- the amplitude modulation ultrasonic wave group is adjusted so that the amplitude in each ultrasonic wave is equal to or lower than the drift velocity, and a control voltage for adjusting the number of ultrasonic waves oscillating as the amplitude modulation ultrasonic wave group is output.
- the phase detection unit 135 includes each ultrasonic wave of the amplitude-modulated ultrasonic wave group detected by the oscillation ultrasonic wave detection unit 131.
- the phase between the waveform of the sound wave and the waveform of the AC voltage output from the AC voltage transmitter 137 is detected.
- the resonance frequency adjustment unit 136 controls the phase of the AC voltage output from the AC voltage transmission unit 137 based on the phase detected by the phase detection unit 135 so that the ultrasonic oscillation unit 120 enters the resonance state. adjust.
- the phase detection unit 135 and the resonance frequency adjustment unit 136 are based on each ultrasonic wave of the amplitude modulation ultrasonic wave group detected by the oscillation ultrasonic wave detection unit 131 and the phase of each ultrasonic wave of the amplitude modulation ultrasonic wave group.
- the “setting unit” of the present invention is configured to set the ultrasonic oscillation unit 120 in the resonance state by controlling the above.
- the AC voltage transmission unit 137 transmits an AC voltage (for example, a sine wave voltage).
- the voltage control amplifier 138 performs control such as modulating the AC voltage transmitted from the AC voltage transmission unit 137 based on the control voltage output from the ultrasonic amplitude adjustment unit 134.
- the power amplifying unit 139 amplifies the AC voltage modulated by the voltage control amplifier 138 and outputs it to the ultrasonic oscillation unit 120.
- the ultrasonic wave oscillation unit 120 In the ultrasonic oscillation unit 120, the AC voltage input from the power amplification unit 139 is supplied to the above-described piezoelectric element (not shown), and distortion based on the AC voltage is generated in the piezoelectric element. As a result, the ultrasonic wave oscillation unit 120 generates an amplitude-modulated ultrasonic wave group in which the amplitude of each ultrasonic wave is modulated.
- V d a drift speed of drug 11 la with respect to the injection target 200
- FIG. 2 is a schematic diagram showing an amplitude-modulated ultrasonic wave group oscillated from the ultrasonic oscillator 120 to the skin 201 of the injection target 200 and its harmonic probability function.
- one amplitude-modulated ultrasonic wave group oscillated from the ultrasonic oscillator 120 to the surface (skin 201) of the injection target 200 includes a plurality of ultrasonic waves each having an amplitude modulated. ing.
- the number of ultrasonic waves that oscillate as a single amplitude-modulated ultrasonic group is the control unit 1
- CPU 133 for example, is determined based on information related to the injection amount of the drug 111a input (set) from the information input unit 140.
- control unit 130 controls the amplitude of each ultrasonic wave of the amplitude-modulated ultrasonic wave group with respect to the elapsed time (t) from the start of oscillation of one amplitude-modulated ultrasonic wave group.
- Slope V this gradient can also be said to be the velocity at the amplitude of each ultrasonic wave with respect to the elapsed time (t)
- the amplitude of each ultrasonic wave is controlled to be equal to or lower than the drift velocity V.
- the gradient (slope) of the dashed line segment connecting the amplitudes of the ultrasonic waves is V.
- control unit 130 determines the amplitude of each ultrasonic wave of one amplitude-modulated ultrasonic wave group from the first ultrasonic wave at the start of oscillation of the amplitude-modulated ultrasonic wave group. Control is performed to increase monotonically up to the last ultrasonic wave related to the number of ultrasonic waves oscillated determined based on the information related to the injection amount of 11 la. In other words, the amplitude of each ultrasonic wave is monotonously increased with the gradient V.
- control unit 130 performs control on the last ultrasonic wave of one amplitude-modulated ultrasonic wave group, and then performs the next amplitude-modulated ultrasonic wave group from the ultrasonic wave oscillating unit 120. Control is performed so that the shape of the oscillating amplitude-modulated ultrasonic wave group has the sawtooth shape shown by the dashed line in FIG.
- Equation (5) represents Young's modulus
- ⁇ represents strain amplitude
- the diffusion frequency ⁇ of the diffusing material gives the drift velocity V.
- the acoustic vibration attenuation coefficient of the human body is about 0.15 / cm at an ultrasonic vibration frequency of 80 kHz, it is considered that the human body is a relaxation system.
- the vibration amplitude given to the human body (injected body 200) by the piezoelectric element of the ultrasonic oscillation unit 120 is limited to the positive side of the amplitude pressure function of a sine wave (sin wave). That is, only the positive amplitude of the sin wave is given to the human body (injected body 200) as an impact force.
- Figure 3 shows the equivalent circuit diagram of this dynamic model.
- Equation (11) ⁇ in Equation (11) is expressed as in Equation (12) below, and in Equation (11)
- Equation (13) When the amplitude ⁇ ⁇ shown in Equation (13) is input to the relaxation system shown in FIG. 3, it becomes a product with the relaxation function, and ⁇ is expressed as in Equation (14) below.
- Equation (14) the contribution to the drift velocity V as a vibration term is such that the lower the drive frequency
- Equation (12) indicates the static pressure amplitude that does not depend on the ultrasonic driving frequency ⁇ . Then, when amplitude modulation is applied so as to have a sawtooth shape like the amplitude-modulated ultrasonic wave group shown in FIG. 2, Equation (12) is expressed as Equation (15) below.
- V is a process from the start of oscillation of one amplitude-modulated ultrasonic wave group.
- FIG. 4 shows a comparative example and is a photograph showing a state of diffusion of a drug (a food coloring pigment dissolved in glycerin) when a fixed-amplitude ultrasonic wave is oscillated from an ultrasonic oscillation unit of the drug injection device.
- a and A shown in Fig. 4 are each 30 minutes of fixed amplitude ultrasonic waves from the ultrasonic oscillator.
- this is gelatin and filter paper when the ultrasonic wave is not oscillated from the ultrasonic wave oscillating unit and diffusion is performed by concentration gradient for 30 minutes.
- the colored portions of each gelatin A and B show the red food pigment injected from each filter paper A and B, respectively.
- FIG. 5 is a diagram illustrating a drug (a food coloring pigment dissolved in glycerin) when an amplitude-modulated ultrasonic wave group is oscillated from the ultrasonic oscillation unit 120 of the drug injection device 100 according to the first embodiment of the present invention. It is a photograph showing the state of diffusion.
- a and A shown in FIG. 5 are respectively the amplitude modulation superstructure shown in FIG.
- Oscillation was performed with a wave group oscillation time of 60 seconds.
- B and B shown in Fig. 5 are
- gelatin and filter paper when ultrasonic wave is not oscillated from the ultrasonic wave oscillating unit 120 and diffusion is performed by concentration gradient for 30 minutes.
- the parts show the food colorings injected from the filter papers A and B, respectively.
- FIG. 6 is a diagram illustrating the state in which each drug is injected (specifically, when an amplitude-modulated ultrasonic wave group is oscillated from the ultrasonic oscillation unit of the drug injection device according to the first embodiment of the present invention.
- FIG. 6 is a characteristic diagram showing the diffusion concentration diffused into a 20-cc pure water through a lmm-thick porcine bladder membrane.
- the frequency domain of the amplitude-modulated ultrasound group in which the diffusion concentration with respect to the injection target 200 reaches a peak is the lowest frequency domain among the three types of drugs 11 la. It has become. Insulin has molecular weight nearly 10 times that of Blue No. 1 and Red No. 102, which is in line with the physical theory prediction “Molecular weight is large!
- each ultrasonic wave of the amplitude-modulated ultrasonic wave group oscillated from the ultrasonic wave oscillating unit 120 based on the drift velocity V of the drug 11 la to the injection target 200 is applied.
- ultrasonic waves are used on the surface of the injection target such as the human body.
- the injection target such as the human body.
- each ultrasonic wave of the amplitude-modulated ultrasonic wave group oscillated from the ultrasonic wave oscillation unit 120 based on the information related to the drug 111a input from the information input unit 140.
- the present invention is not limited to this, and it is possible to control the amplitude of sound waves and control the number of ultrasonic waves oscillated as one amplitude-modulated ultrasonic wave group.
- information related to the measured acoustic impedance of the injectable body 200 is input from the information input unit 140, added to the information related to the drug 11 la, Taking into account information related to acoustic impedance, control of the amplitude of each ultrasonic wave of the amplitude-modulated ultrasonic group oscillated from the ultrasonic oscillator 120 and the number of ultrasonic waves oscillated as one amplitude-modulated ultrasonic group It is a form to perform control Good.
- FIG. 7 is a block diagram showing a schematic configuration of a drug injection device 700 according to the second embodiment of the present invention.
- a drug injection device 700 according to the second embodiment is provided with a blood glucose level measurement unit 160 in addition to the drug injection device 100 according to the first embodiment shown in FIG. is there.
- insulin is used as the drug 11 la.
- the blood glucose level measurement unit 160 measures a blood glucose level indicating the concentration of dulcose (blood sugar) in the blood in the body 202 of the injected body 200.
- the blood sugar level measuring unit 160 is configured by the apparatus shown in FIG.
- the CPU 133 in addition to the control in the first embodiment, the CPU 133 further has information related to the blood glucose level (blood glucose level data) measured by the blood glucose level measurement unit 160 equal to or greater than a threshold value. In this case, control is performed to oscillate the amplitude-modulated ultrasonic wave group from the ultrasonic oscillation unit 120. At this time, for example, the CPU 133 also performs control to drive the valve 114 that supplies the drug 11 la from the storage unit 111 to the injection target 200. This is because the blood glucose level of the injectable body 200 is lowered by injecting insulin, which is the drug 11 la, into the injectable body 200.
- the CPU 133 generates the amplitude-modulated ultrasonic wave group from the ultrasonic oscillation unit 120 when the information (blood glucose level data) related to the blood glucose level measured by the blood glucose level measuring unit 160 is less than the threshold value. Control to stop shaking. At this time, the CPU 133 also performs control to drive the valve 114 that stops the supply of the drug 11 la from the storage unit 111 to the injection target 200, for example.
- the information related to the threshold compared with the information related to blood glucose level (blood glucose level data) in CPU 133 is input from information input unit 140, for example.
- information input unit 140 for example, in the present embodiment, it is assumed that a value of 130 mg / dl is input from the information input unit 140 as the blood glucose level threshold.
- the ultrasonic oscillation unit 120 Since the oscillation of the amplitude-modulated ultrasonic wave group is stopped, in addition to the effects in the first embodiment, the injection (further injection) is further supplied from the state in which the drug (insulin) is sufficiently supplied to the injection target such as the human body. The situation where the drug is excessively supplied to the body can be avoided. This also makes it possible to ensure the safety of the injection target such as a human body.
- the force that has been described assuming a human body as the injection target 200 is not limited to this in the present invention. Even so, it is applicable.
- each means of the control unit 130 of Fig. 1 and Fig. 7 constituting the drug injection device according to each embodiment of the present invention described above is operated by a program stored in a RAM or ROM of a computer. Can be realized. This program and a computer-readable storage medium storing the program are included in the present invention.
- the program is recorded on a storage medium such as a CD-ROM, or provided to a computer via various transmission media.
- a storage medium for recording the program a flexible disk, a hard disk, a magnetic tape, a magneto-optical disk, a nonvolatile memory card, and the like can be used in addition to the CD-ROM.
- a transmission medium of the program a communication medium in a computer network (LAN, Internet or other WAN, wireless communication network, etc.) system for propagating and supplying program information as a carrier wave can be used.
- examples of the communication medium at this time include a wired line such as an optical fiber and a wireless line.
- the present invention is achieved by executing a program supplied by a computer. It is not restricted to the aspect in which the function of the medicine injection device concerning each embodiment of is realized.
- the function of the drug injection device according to each embodiment of the present invention is realized in cooperation with an OS (operating system) or other application software, etc. Even in such a case, the program is included in the present invention. Further, when all or part of the processing of the supplied program is performed by a function expansion board or function expansion unit of the computer, the function of the drug injection device according to each embodiment of the present invention is realized. In any case, a power program is included in the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Percussion Or Vibration Massage (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07831684.1A EP2103324B1 (en) | 2006-11-14 | 2007-11-13 | Drug injecting device |
CN200780042035XA CN101534895B (zh) | 2006-11-14 | 2007-11-13 | 药物注入装置 |
US12/514,950 US8010188B2 (en) | 2006-11-14 | 2007-11-13 | Drug injecting device |
JP2008544134A JP4706069B2 (ja) | 2006-11-14 | 2007-11-13 | 薬物注入装置 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-308270 | 2006-11-14 | ||
JP2006308270 | 2006-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008059810A1 true WO2008059810A1 (fr) | 2008-05-22 |
Family
ID=39401618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/071954 WO2008059810A1 (fr) | 2006-11-14 | 2007-11-13 | Dispositif d'injection de médicament |
Country Status (6)
Country | Link |
---|---|
US (1) | US8010188B2 (ja) |
EP (1) | EP2103324B1 (ja) |
JP (1) | JP4706069B2 (ja) |
KR (1) | KR101214764B1 (ja) |
CN (1) | CN101534895B (ja) |
WO (1) | WO2008059810A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011108713A1 (ja) * | 2010-03-05 | 2011-09-09 | 国立大学法人 鹿児島大学 | 物質排出装置 |
WO2016147297A1 (ja) * | 2015-03-16 | 2016-09-22 | 株式会社日立製作所 | 薬液投与装置、及びその作動方法 |
WO2024005144A1 (ja) * | 2022-07-01 | 2024-01-04 | 国立大学法人東京大学 | 体表面潰瘍治癒促進装置 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6329662A (ja) * | 1986-07-10 | 1988-02-08 | エラン トランスダ−マル リミテツド | 経皮的薬物投与装置 |
JPH04295362A (ja) * | 1991-03-22 | 1992-10-20 | Katsuro Tachibana | 超音波治療用制御装置 |
JPH0578241A (ja) * | 1991-03-06 | 1993-03-30 | Dompe Farmaceut Spa | ケトプロフエンリジン塩を含む局所用親水性医薬組成物 |
JPH11511360A (ja) * | 1995-08-29 | 1999-10-05 | スペクトルクス,インコーポレイテッド | 薬物送達および鑑視適用のためのヒト皮膚の微細穿孔 |
WO2003061753A1 (fr) | 2002-01-21 | 2003-07-31 | Matsushita Electric Works, Ltd. | Dispositif, necessaire et procede de diffusion percutanee par ultrasons |
JP2004249025A (ja) | 2003-02-17 | 2004-09-09 | Hiroto Tateno | 生体光音響共鳴非侵襲生化学成分分析器と血液成分測定法 |
JP2006518640A (ja) * | 2003-02-19 | 2006-08-17 | セカンド ステージ ベンチャーズ インコーポレイテッド | 経皮的薬物送達方法及び装置 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3196384A (en) * | 1962-02-27 | 1965-07-20 | Ibm | Ultrasonic amplifier |
US3234482A (en) * | 1963-04-23 | 1966-02-08 | Bell Telephone Labor Inc | Stabilized ultrasonic amplifier |
US3325748A (en) * | 1964-05-01 | 1967-06-13 | Texas Instruments Inc | Piezoelectric semiconductor oscillator |
US3990452A (en) * | 1975-06-13 | 1976-11-09 | Fibra-Sonics, Inc. | Medical machine for performing surgery and treating using ultrasonic energy |
US4195244A (en) * | 1978-07-26 | 1980-03-25 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | CdS Solid state phase insensitive ultrasonic transducer |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
JP2907342B2 (ja) * | 1988-01-29 | 1999-06-21 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | イオン滲透非侵襲的サンプリングまたは送出装置 |
JPH02144077A (ja) * | 1988-11-25 | 1990-06-01 | Olympus Optical Co Ltd | 薬物投与装置 |
JPH03297475A (ja) * | 1990-04-16 | 1991-12-27 | Ken Ishihara | 共振音波により薬物の放出を制御する方法 |
WO1994004907A1 (en) * | 1992-08-17 | 1994-03-03 | Commonwealth Scientific And Industrial Research Organisation | A method and apparatus for determining the particle size distribution, the solids content and the solute concentration of a suspension of solids in a solution bearing a solute |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5445611A (en) * | 1993-12-08 | 1995-08-29 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal delivery with ultrasound and chemical enhancers |
US5458140A (en) * | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
US5771890A (en) * | 1994-06-24 | 1998-06-30 | Cygnus, Inc. | Device and method for sampling of substances using alternating polarity |
US5895362A (en) * | 1996-02-23 | 1999-04-20 | Abbott Laboratories | Transdermal transport using ultrasonic standing waves |
US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
US6527716B1 (en) * | 1997-12-30 | 2003-03-04 | Altea Technologies, Inc. | Microporation of tissue for delivery of bioactive agents |
US6333485B1 (en) * | 1998-12-11 | 2001-12-25 | International Business Machines Corporation | Method for minimizing sample damage during the ablation of material using a focused ultrashort pulsed beam |
US6231528B1 (en) * | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
US20030078499A1 (en) * | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
US6853858B2 (en) * | 2000-05-08 | 2005-02-08 | Brainsgate, Ltd. | Administration of anti-inflammatory drugs into the central nervous system |
US7597692B2 (en) * | 2000-06-08 | 2009-10-06 | Massachusetts Institute Of Technology | Microscission processes and procedures |
WO2002022027A1 (en) | 2000-08-24 | 2002-03-21 | Encapsulation Systems, Inc. | Ultrasonically enhanced substance delivery system and device |
US7556621B2 (en) * | 2001-06-29 | 2009-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Optically controlled microfluidic chip |
US20030065285A1 (en) * | 2001-07-23 | 2003-04-03 | Higuchi William I. | Method and apparatus for increasing flux during reverse iontophoresis |
US20050075598A1 (en) | 2001-08-24 | 2005-04-07 | Redding Bruce K. | Method and apparatus for the measurement of real time drug delivery through the use of a wearable monitor and sensor attached to a transdermal drug delivery device |
CA2612866A1 (en) * | 2005-05-11 | 2006-11-23 | Corium International, Inc. | Permeabilization of biological membranes |
US9028748B2 (en) * | 2006-02-24 | 2015-05-12 | Nanovibronix Inc | System and method for surface acoustic wave treatment of medical devices |
-
2007
- 2007-11-13 JP JP2008544134A patent/JP4706069B2/ja active Active
- 2007-11-13 WO PCT/JP2007/071954 patent/WO2008059810A1/ja active Application Filing
- 2007-11-13 US US12/514,950 patent/US8010188B2/en not_active Expired - Fee Related
- 2007-11-13 EP EP07831684.1A patent/EP2103324B1/en not_active Not-in-force
- 2007-11-13 CN CN200780042035XA patent/CN101534895B/zh not_active Expired - Fee Related
- 2007-11-13 KR KR1020097009819A patent/KR101214764B1/ko not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6329662A (ja) * | 1986-07-10 | 1988-02-08 | エラン トランスダ−マル リミテツド | 経皮的薬物投与装置 |
JPH0578241A (ja) * | 1991-03-06 | 1993-03-30 | Dompe Farmaceut Spa | ケトプロフエンリジン塩を含む局所用親水性医薬組成物 |
JPH04295362A (ja) * | 1991-03-22 | 1992-10-20 | Katsuro Tachibana | 超音波治療用制御装置 |
JPH11511360A (ja) * | 1995-08-29 | 1999-10-05 | スペクトルクス,インコーポレイテッド | 薬物送達および鑑視適用のためのヒト皮膚の微細穿孔 |
WO2003061753A1 (fr) | 2002-01-21 | 2003-07-31 | Matsushita Electric Works, Ltd. | Dispositif, necessaire et procede de diffusion percutanee par ultrasons |
JP2004249025A (ja) | 2003-02-17 | 2004-09-09 | Hiroto Tateno | 生体光音響共鳴非侵襲生化学成分分析器と血液成分測定法 |
JP2006518640A (ja) * | 2003-02-19 | 2006-08-17 | セカンド ステージ ベンチャーズ インコーポレイテッド | 経皮的薬物送達方法及び装置 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2103324A4 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011108713A1 (ja) * | 2010-03-05 | 2011-09-09 | 国立大学法人 鹿児島大学 | 物質排出装置 |
JP2011182883A (ja) * | 2010-03-05 | 2011-09-22 | Kagoshima Univ | 物質排出装置 |
CN102753232A (zh) * | 2010-03-05 | 2012-10-24 | 国立大学法人鹿儿岛大学 | 物质排出装置 |
WO2016147297A1 (ja) * | 2015-03-16 | 2016-09-22 | 株式会社日立製作所 | 薬液投与装置、及びその作動方法 |
JPWO2016147297A1 (ja) * | 2015-03-16 | 2017-06-22 | 株式会社日立製作所 | 薬液投与装置、及びその作動方法 |
WO2024005144A1 (ja) * | 2022-07-01 | 2024-01-04 | 国立大学法人東京大学 | 体表面潰瘍治癒促進装置 |
Also Published As
Publication number | Publication date |
---|---|
EP2103324A4 (en) | 2011-10-26 |
CN101534895A (zh) | 2009-09-16 |
US20100049118A1 (en) | 2010-02-25 |
CN101534895B (zh) | 2012-10-03 |
KR101214764B1 (ko) | 2012-12-21 |
EP2103324A1 (en) | 2009-09-23 |
EP2103324B1 (en) | 2013-07-03 |
JPWO2008059810A1 (ja) | 2010-03-04 |
KR20090084867A (ko) | 2009-08-05 |
JP4706069B2 (ja) | 2011-06-22 |
US8010188B2 (en) | 2011-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schoellhammer et al. | Skin permeabilization for transdermal drug delivery: recent advances and future prospects | |
CN101670143B (zh) | 一种医用输药装置 | |
Smith et al. | Ultrasound-mediated transdermal in vivo transport of insulin with low-profile cymbal arrays | |
CA2584638A1 (en) | Medical device for generating transient bubbles | |
JP2001511041A (ja) | 生物体液を獲得するための装置 | |
KR101022201B1 (ko) | 경피약물전달 촉진을 위한 초음파 장치 | |
ATE246902T1 (de) | Steuerung von kontrastverbesserter bildgebung | |
JP2007525276A5 (ja) | ||
DE602006018066D1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur senkung der lipid- und blutzuckerspiegel | |
WO2008059810A1 (fr) | Dispositif d'injection de médicament | |
Fiorillo et al. | Low-frequency ultrasound in medicine: An in vivo evaluation | |
CA2245712A1 (en) | Transdermal transport using ultrasonic standing waves | |
Kost | Ultrasound-assisted insulin delivery and noninvasive glucose sensing | |
Lee et al. | Noninvasive ultrasonic transdermal insulin delivery in rabbits using the light-weight cymbal array | |
Krawiec et al. | Impact of Pulsatile Flow on Hemodynamic Energy in a M edos D eltastream DP 3 Pediatric Extracorporeal Life Support System | |
Jabbari et al. | Developing a commercial air ultrasonic ceramic transducer to transdermal insulin delivery | |
Park et al. | Noninvasive ultrasonic glucose sensing with large pigs (∼ 200 Pounds) using a lightweight cymbal transducer array and biosensors | |
JPH02144077A (ja) | 薬物投与装置 | |
JP2006518640A (ja) | 経皮的薬物送達方法及び装置 | |
CN106175840A (zh) | 一种提取组织液的方法 | |
Coiado et al. | The role of the duty factor in ultrasound-mediated cardiac stimulation | |
CN205948138U (zh) | 一种捕获并去除输液管中气泡的装置 | |
WO2011108713A1 (ja) | 物質排出装置 | |
TWI311917B (ja) | ||
Al-Bataineh et al. | In-vivo evaluation of a noninvasive transdermal insulin delivery system utilizing ultrasound transducers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780042035.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07831684 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097009819 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008544134 Country of ref document: JP Ref document number: 12514950 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007831684 Country of ref document: EP |